NCT02750592 - Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 22, 2016

Primary Completion Date

July 5, 2017

Study Completion Date

May 16, 2018

Conditions

Ankylosing Spondylitis

Interventions

DRUG

Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.

Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.

Trial Locations (10)

Novartis Investigative Site, Kitakyushu

Novartis Investigative Site, Kita-gun

Novartis Investigative Site, Nankoku

Novartis Investigative Site, Tenri

Novartis Investigative Site, Okayama

Novartis Investigative Site, Kawachi-Nagano

Novartis Investigative Site, Suita

Novartis Investigative Site, Bunkyo Ku

Novartis Investigative Site, Chuo Ku

Novartis Investigative Site, Shinjuku-ku